



RECEIVED

MAY 08 2002

ATTORNEY DOCKET NO. 2004229-0031

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hansen, et al.
Serial No.: 10/076,363
Filing Date: February 15, 2002
Title: SYSTEM FOR AXIAL PATTERN ANALYSIS OF MULTICELLULAR ORGANISMS

Examiner: NYA
Art Unit: NYA

#5-
JDS
6542
AS

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner For Patents, Washington, D.C. 20231 on April 30, 2002

Sir:

Kathryn Hart Rogerson

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE

UNDER 37 CFR §§1.56, 1.97 AND 1.98

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants respectfully request consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

(Select A, B or C below)

A: ☒ This Information Disclosure Statement has been filed:

(check 1, 2 and/or 3 below)

1. ☒ within three months of the filing date of the above identified U.S. Patent application;
2. ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International application; and/or
3. ☐ before the mailing date of the first Office Action on the merits in the above-identified application.

No fee or certification is required.

- B. ☐ This Information Disclosure Statement has been filed more than three months after the filing date of the present application and after the mailing date of this first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311.

(check 1 or 2 below)

1. ☐ The fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed; or
2. ☐ Applicants hereby certify, as specified in 37 C.F.R. §1.97(e), that
(check a or b below)
 - a. ☐ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart for this application not more than three months prior to the filing of this Statement; or
 - b. ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart for this application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Statement.
- c. ☐ items indicated by an asterisk were identified in a recent review of related files.

- C. ☐ This Information Disclosure Statement has been filed after the mailing date of either a Final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311 and before payment of an Issue Fee.

(check 1, 2, and 3 below)

1. ☐ The Applicant hereby certifies, as specified in 37 C.F.R. §1.97(e), that:
(check a or b below)
 - a. ☐ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign Patent

Office in a counterpart for this application not more than three months prior to the filing of this Statement.

- b. ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart for this application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Statement.
2. ☐ A Petition requesting consideration of the Information Disclosure Statement is attached.
3. ☐ The Petition Fee of \$130 as set forth in 37 C.F.R. §1.17(i)(1) is enclosed.

PART II - Information Cited

- A. ☒ The Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.
- B. ☐ The Applicant hereby makes the following additional information of record in the above-identified application:

PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

- A. ☐ The following is a concise explanation of the relevance of each non-English language reference listed on the attached form PTO-1449 (modified):
- B. ☐ The following are remarks concerning the other information cited:

A. [X] Copies of references
(check 1 or 2 below)

1. ☒ A copy of each of the references cited on the attached form PTO-1449 (modified) is enclosed;
 2. ☐ Copies of certain of the references cited on the attached form PTO-1449 (modified) are not enclosed because each of these references (indicated by asterisk) was previously cited by or submitted to the Office in a prior application, which prior application is relied upon for an earlier filing date under 35 U.S.C. § 120.
- B. ☒ It is respectfully requested that:
(check 1, 2, and 3 below)
1. ☒ The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
 2. ☒ The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application;
 3. ☒ The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.
- C. ☒ By submitting this Information Disclosure Statement, Applicants make no representation that a search has been performed, of the extent of any search performed, or that more material information may not exist.


- D. ☒ By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).
- E. ☒ By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.
- F. ☒ Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

An early and favorable action is hereby requested.

Please charge any additional fees or credit any overpayments to our Deposit Account No. 03-1721.

Respectfully submitted,

Dated: 4/8/2002

By: 
Brenda Herschbach Jarrell, Ph.D.
Registration Number 39,223

CHOATE, HALL & STEWART
Exchange Place
53 State Street
Boston, Massachusetts 02109
Telephone: (617) 248-5000
Facsimile: (617) 248-4000

Form PTO-1449
(REV. 8-83)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket:
2004229-0031

In re Application
No. 10/076,363

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant: Hansen, et al.

Filing Date: 2/15/02

Group: NYA

U. S. PATENT DOCUMENTS

RECEIVED

Examiner's
Initials

U.S. Patent No.

Applicant

Issue Date

MAY 08 2002

4,284,412

Hansen et al.

August 18, 1981

TECH CENTER 1600/2900

U. S. PATENT APPLICATIONS

Examiner's
Initials

Serial No.
or Publication No.

Applicant

Filing Date

09/378,634

Hansen

Pending

09/465,215

Hansen

Pending

FOREIGN PATENT DOCUMENTS

Examiner's
Initials

Translation

Yes

No

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449
(REV. 8-83)



U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket:
2004229-0031

In re Application
No. 10/076,363

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant: Hansen, et al.

Filing Date: 02/15/00

Group: NYA

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

- Burdine, et al., "egl-17 encodes an invertebrate fibroblast growth factor family member required specifically for sex myoblast migration in *Caenorhabditis elegans*," Proc. Natl. Acad. Sci., U.S.A. 94:2433-2437.
- Burdine, et al., "EGL-17(FGF) expression coordinates the attraction of the migrating sex myoblasts with vulval induction in *C. elegans*," Development 125:1083-1093.
- Byerly, L., RC. Cassada and RL. Russell. Machine for rapidly counting and measuring the size of small nematodes. Rev Sci Instrum. 1975 May; 46(5):517-22.
- Dubelaar, G.B., A.C. Groenwegen, W. Stokdijk, G.J. van den Engh, and J.W. Visser, "Optical Plankton Analyser: a Flow Cytometer for Plankton Analysis, II: Specifications", Cytometry 1989 Sept 10 (5): 529-539
- Harris, J., Honigberg, L., Robinson, N., and Kenyon, C. (1996). Neuronal cell migration in *C. elegans*: regulation of Hox gene expression and cell position. Development, 122, 3117-31.
- Kenyon, C. (1986). A gene involved in the development of the posterior body region of *C. elegans*. Cell, 46, 477-487.
- Korswagen, H. C., Herman, M. A., and Clevers, H. C. (2000). Specificity of β -catenin signalling in *C. elegans*. Nature, 406 (3 August 2000): 527-532.
- Lejeune Et al., (1995) Wnta cloning, expression and up-regulation in human primary breast cancers Clin. Cancer Res. 1: 215-222.
- Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and Kinzler, K. W. (1997). Activation of beta -catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science, 275, 1787-90.
- Nusse, R., and Varmus, H. E. (1982). Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell, 31, 99-109.
- Peeters, J.C., G.B. Dubelaar, J. Ringelberg, and J.W. Visser, "Optical Plankton Analyser: a Flow Cytometer for Plankton Analysis, I: Design Considerations" Cytometry 1989 Sept 10 (5): 522-528
- Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., and Polakis, P. (1997). Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science, 275, 1790-2.
- Salser, S.- J., and Kenyon, C. (1992). Activation of a *C. elegans Antennapedia* homologue in migrating cells controls their direction of migration. Nature, 355, 255-8.
- Tsien, R. Rosy Down for Fluorescent Proteins. Nature Biotechnology (1999) 17: 956-57

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.